On July 31, DexCom rose 7.4% in regular trading, trading around $81.75 per share with turnover of approximately $127 million. The rally was primarily driven by the company's Q2 earnings report that comprehensively exceeded market expectations alongside an upward revision to full-year revenue guidance.

Specifically, DexCom reported Q2 adjusted earnings of $0.70 per diluted share, beating the analyst consensus estimate of $0.61 by 14.75% and representing a 45.83% increase year-over-year from $0.48. Revenue for the quarter reached $1.308 billion, surpassing the expected $1.29 billion and growing approximately 13% year-over-year, fueled by robust demand for continuous glucose monitoring systems. The company raised its full-year revenue guidance to $5.18 billion-$5.25 billion, lifting the prior lower bound from $5.16 billion.

Following the results, BTIG adjusted its price target on DexCom to $90 from $80 while maintaining a Buy rating. The average analyst price target now stands at $91.42, reflecting strengthened confidence in the company's growth trajectory driven by rising diabetes care awareness and consumer preference for non-invasive monitoring technology.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)